Evidence map›Paper›PMID 39522676›Full record

ArticleNeuropharmacology2025

MRS3997, a dual adenosine A

Ilaria Dettori, Irene Bulli, Martina Venturini, Giada Magni, Federica Cherchi, Francesca Rossi, Hobin Lee, Felicita Pedata, Kenneth A Jacobson, Anna Maria Pugliese and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ilaria DettoriDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy. Electronic address: ilaria.dettori@unifi.it.
Irene BulliDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy.
Martina VenturiniDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy.
Giada MagniInstitute of Applied Physics "Nello Carrara", National Research Council (IFAC-CNR), Sesto Fiorentino, Florence, Italy.
Federica CherchiDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy.
Francesca RossiInstitute of Applied Physics "Nello Carrara", National Research Council (IFAC-CNR), Sesto Fiorentino, Florence, Italy.
Hobin LeeMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabe-tes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Felicita PedataDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy.
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabe-tes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Anna Maria PuglieseDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy. Electronic address: annamaria.pugliese@unifi.it.
Elisabetta CoppiDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, Florence, Italy.

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

The endogenous neuromodulator adenosine is massively released during hypoxic/ischemic insults and differentially modulates post-ischemic damage depending on the expression and recruitment of its four metabotropic receptor subtypes, namely A

Indexed as

Adenosine A2 Receptor AgonistsInfarction, Middle Cerebral ArteryNeuroinflammatory DiseasesAnimalsBrain IschemiaCytokinesDisease Models, AnimalMaleMicrogliaNeuroprotective AgentsPurinesRatsRats, WistarReceptor, Adenosine A2AReceptor, Adenosine A2BAdenosine A2 Receptor AgonistsCytokinesistradefyllineNeuroprotective AgentsPurinesReceptor, Adenosine A2AReceptor, Adenosine A2BAdenosine A(2A) receptorsAdenosine A(2B) receptorsCerebral ischemiaMultitarget drugsNeuroinflammation

Identifiers

PMID39522676
PMCPMC11789432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.